Next Science Ltd (ASX: NXS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Next Science Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $97.72 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 291.70 million
Earnings per share -0.070
Dividend per share N/A
Year To Date Return 5.88%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Next Science Ltd (ASX: NXS)
    Latest News

    Man pointing an upward line on a bar graph symbolising a rising share price.
    Share Gainers

    Why ANZ, Next Science, Macmahon, and Pointsbet shares are racing higher

    These ASX shares are having a good session on Thursday.

    Read more »

    Man pointing at a blue rising share price graph.
    Healthcare Shares

    Guess which ASX healthcare share is booming 28% on a sales boost

    Investors are bidding up the ASX healthcare share after the company reported it’s on track to substantially exceed product sales…

    Read more »

    Rising arrow on a blue graph symbolising a rising share price.
    Healthcare Shares

    Next Science shares defy ASX market slump to surge 8%

    Next Science shares are set to finish Thursday's trading session on a high note.

    Read more »

    A male ASX investor sits cross-legged with a laptop computer in his lap with a slightly crazed, happy, excited look on his face while next to him a graphic of a rocket shoots upwards with graphics of stars scattered around it
    Healthcare Shares

    Here's why the Next Science (ASX:NXS) share price is rocketing 11% today

    The company's shares are on fire this Monday.

    Read more »

    A man scratches his head in confusion.
    Healthcare Shares

    What happened to the Next Science (ASX:NXS) share price last earnings season?

    Shares in the Aussie biotech were smashed on Friday before recovering late in the day

    Read more »

    medical doctor performing surgery using surgical instruments
    Share Gainers

    Next Science (ASX:NXS) share price jumps on record revenue growth

    A surge in revenue during the first half of 2021 puts the Next Science share price in the green today...

    Read more »

    Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
    Technology Shares

    Next Science (ASX:NXS) share price swings on lowered earnings update

    The Next Science share price went into a spin after a lowered earnings guidance sent investors running.

    Read more »

    three excited doctors with hands in the air
    Healthcare Shares

    Here's why the Next Science (ASX:NXS) share price finished higher today

    The medical research company has finished the day strongly after one of its products was given TGA approval.

    Read more »

    investor looking up as if watching asx share price
    Healthcare Shares

    Next Science (ASX:NXS) share price falls despite 'exciting future ahead'

    The Next Science Ltd (ASX: NXS) share price slumped today following the company's 2021 AGM presentation. Let's take a closer look.

    Read more »

    A boy looks up and points his fingers to the sky in celebration pose.
    Share Gainers

    Why Doctor Care Anywhere, Next Science, NIB, & Talga are charging higher

    Next Science Ltd (ASX:NXS) and NIB Holdings Limited (ASX:NHF) are two of four ASX shares that are charging notably higher…

    Read more »

    Rising healthcare ASX share price represented by doctor giving thumbs up
    Healthcare Shares

    Why the Next Science (ASX:NXS) share price opened 40% higher

    The Next Science Ltd (ASX: NXS) share price is shooting for the moon after the company's latest announcement. Click on…

    Read more »

    Two men react in shock at Evolution share price drop record profit
    Share Fallers

    Why Alumina, Delorean, Next Science, & Pushpay shares are tumbling lower

    Next Science Ltd (ASX:NXS) and Pushpay Holdings Ltd (ASX:PPH) shares are two of four tumbling lower on Tuesday. Here's why...

    Read more »

    NXS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Next Science Ltd

    Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

    NXS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $0.34 $-0.03 -8.33% 64,481 $0.36 $0.36 $0.34
    26 Mar 2024 $0.36 $-0.02 -5.26% 65,429 $0.38 $0.38 $0.36
    25 Mar 2024 $0.38 $0.00 0.00% 11,768 $0.38 $0.38 $0.37
    22 Mar 2024 $0.38 $0.01 2.70% 18,359 $0.37 $0.38 $0.37
    21 Mar 2024 $0.37 $-0.01 -2.67% 24,496 $0.36 $0.37 $0.36
    20 Mar 2024 $0.38 $-0.01 -2.63% 9,471 $0.35 $0.38 $0.35
    19 Mar 2024 $0.38 $-0.01 -2.60% 65,838 $0.38 $0.38 $0.36
    18 Mar 2024 $0.39 $0.00 0.00% 14,540 $0.38 $0.39 $0.38
    15 Mar 2024 $0.39 $0.00 0.00% 136,787 $0.38 $0.39 $0.37
    14 Mar 2024 $0.39 $0.01 2.63% 3,058 $0.39 $0.39 $0.39
    13 Mar 2024 $0.38 $0.01 2.70% 146,079 $0.37 $0.39 $0.37
    12 Mar 2024 $0.37 $0.01 2.74% 280,637 $0.37 $0.38 $0.35
    11 Mar 2024 $0.37 $0.01 2.82% 21,728 $0.36 $0.37 $0.36
    08 Mar 2024 $0.36 $-0.02 -5.41% 139,983 $0.37 $0.38 $0.35
    07 Mar 2024 $0.37 $0.00 0.00% 37,027 $0.38 $0.38 $0.37
    06 Mar 2024 $0.37 $-0.02 -5.13% 52,542 $0.37 $0.38 $0.36
    05 Mar 2024 $0.39 $0.03 8.33% 78,841 $0.37 $0.39 $0.36
    04 Mar 2024 $0.36 $0.01 2.86% 68,008 $0.34 $0.36 $0.34
    01 Mar 2024 $0.35 $0.04 12.70% 62,138 $0.32 $0.35 $0.32
    29 Feb 2024 $0.32 $-0.01 -3.13% 135,685 $0.31 $0.33 $0.31
    28 Feb 2024 $0.32 $-0.03 -8.70% 256,155 $0.35 $0.35 $0.29
    27 Feb 2024 $0.35 $-0.01 -2.86% 211,152 $0.35 $0.38 $0.34

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    01 Nov 2023 Grant Hummel Issued 309,524 $130,000
    Placement.
    01 Nov 2023 Aileen Stockburger Issued 524,801 $220,416
    Placement.
    01 Nov 2023 Harry Hall(IV) Issued 200,000 $54,440
    Placement.
    31 Jul 2023 Judith Mitchell Transfer 420,000 $220,500
    Off-market transfer. Assuming off-market transfer of shares
    31 Jul 2023 Judith Mitchell Transfer 420,000 $220,500
    Off-market transfer. Assuming off-market transfer of shares

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Grant Hummel Non-Executive Director Aug 2023
    Mr Hummel has been a partner of a major Australian law firm for over fifteen years. He has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Mr Hummel has been a non-executive director of GLG Corp Ltd since 2018 and serves as the Chair of GLG's Nomination and Remuneration Committee and as a member of GLG's Audit and Risk Committee.
    Mr Daniel (Dan) Spira Non-Executive Director Oct 2017
    Mr Spira is the CEO of iNova Pharmaceuticals (since 2017) which is a leading multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously he was at Bausch Health (2011-2015) as Vice President and GM-North America (with responsibility for a portfolio of businesses spanning Vision Care, Dermatology and Aesthetic Devices) and was also Managing Director, Pacific region. Prior to that, Mr Spira spent over 15 years at Johnson & Johnson Inc in various roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions.
    Ms Aileen Stockburger Non-Executive DirectorNon-Executive Chairman Oct 2018
    Prior to joining Next Science, Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms.
    Ms Katherine (Kathy) Ostin Non-Executive Director Oct 2023
    Ms Ostin is a non-executive director and audit and risk committee chair. Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017. During her 24 years with KPMG, Ms Ostin worked in Australia, the US, Asia, and the UK. Ms Ostin currently serves as a Non-Executive Director of 3P Learning Limited (ASX:3PL), dusk Group Limited (ASX:DSK), Capral Limited (ASX:CAA) and Alex Corporation Limited.
    Mr Harry Thomas Hall(IV) Chief Executive OfficerManaging Director Jul 2023
    Mr Hall has 28 years in the global medical device industry, I.V. has held general management roles including product development, global strategic marketing, commercial operations, and sales leadership. I.V. joined DePuy Synthes, a subsidiary of Johnson and Johnson (NYSE: JNJ) in 1997 where he held senior roles including: Global Vice President - MedTech R&D and Worldwide President Trauma, Extremities, Craniomaxillofacial & Animal Health. I.V. was most recently a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes and completed the launch of the first surgical robot developed by JNJ / DePuy Synthes. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, I.V.
    Ms Gillian Maria Nairn Company Secretary Jun 2018
    -
    Jacqueline Butler Chief Financial Officer
    -
    Matthew Myntti Chief Technology Officer
    -
    Gillian Maria Nairn Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Auckland Trust Company Ltd 56,019,938 26.08%
    Walker Group Holdings Pty Limited 26,877,123 12.51%
    Hsbc Custody Nominees (Australia) Limited A/C 2 11,563,164 5.38%
    Dr Matthew Franco Myntti 10,472,969 4.88%
    Ubs Nominees Pty Ltd 6,959,201 3.24%
    Hsbc Custody Nominees (Australia) Limited 5,338,314 2.49%
    Judith Lee Mitchell 5,129,936 2.39%
    Mr Charles Robert Dirck Wittenoom 3,000,000 1.40%
    Sandhurst Trustees Ltd <Endeavor Asset Mgmt Mda A/C> 2,845,857 1.32%
    J P Morgan Nominees Australia Pty Limited 2,789,351 1.30%
    Citicorp Nominees Pty Limited 2,634,289 1.23%
    National Nominees Limited 2,474,702 1.15%
    Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 1,973,603 0.92%
    Bond Street Custodians Limited <Lam1 D08047 A/C> 1,460,427 0.68%
    Mr James Fong Seeto 1,400,000 0.65%
    Brook St Smsf Pty Ltd <Brook St Smsf A/C> 1,255,702 0.58%
    G & N Lord Superannuation Pty Ltd <Gnr Superannuation Fund A/C> 965,000 0.45%
    Twenty Fifth Elporto Pty Limited <Twenty Fifth Elporto Sf A/C> 900,000 0.42%
    Ka-Tet Pty Ltd <The Rosenrot Trust> 890,500 0.41%
    Mrs Desiree Hancox Darroch 815,500 0.38%

    Profile

    since

    Note